Palmar plantar erythrodysesthesia primary prevention: Difference between revisions
Jump to navigation
Jump to search
Mchitsazan (talk | contribs) No edit summary |
No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Avoiding excessive manual work and walking, wound care to prevent infection, limb elevation, cold compresses, avoiding extreme temperatures, analgesics, creams | Avoiding excessive manual work and walking, [[wound]] care to prevent [[infection]], [[limb]] [[elevation]], [[Cold compression therapy|cold compresses]], avoiding extreme [[temperatures]], [[Analgesic|analgesics]], and creams/[[Emollient|emollients]] are suggested to [[Prevention|prevent]], delay onset, and/or decrease the severity of palmar plantar erythrodysesthesia (PPE). | ||
==Primary | ==Primary Prevention== | ||
A number of measures have been suggested to prevent, delay onset and/or decrease the severity of PPE. General measures include:<ref name="pmid2061446">{{cite journal| author=Baack BR, Burgdorf WH| title=Chemotherapy-induced acral erythema. | journal=J Am Acad Dermatol | year= 1991 | volume= 24 | issue= 3 | pages= 457-61 | pmid=2061446 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2061446 }} </ref> <ref name="pmid10071309">{{cite journal| author=Susser WS, Whitaker-Worth DL, Grant-Kels JM| title=Mucocutaneous reactions to chemotherapy. | journal=J Am Acad Dermatol | year= 1999 | volume= 40 | issue= 3 | pages= 367-98; quiz 399-400 | pmid=10071309 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10071309 }} </ref> <ref name="pmid15341880">{{cite journal| author=Lassere Y, Hoff P| title=Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). | journal=Eur J Oncol Nurs | year= 2004 | volume= 8 Suppl 1 | issue= | pages= S31-40 | pmid=15341880 | doi=10.1016/j.ejon.2004.06.007 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15341880 }} </ref> <ref name="pmid12660565">{{cite journal| author=Gerbrecht BM| title=Current Canadian experience with capecitabine: partnering with patients to optimize therapy. | journal=Cancer Nurs | year= 2003 | volume= 26 | issue= 2 | pages= 161-7 | pmid=12660565 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12660565 }} </ref> | A number of measures have been suggested to [[Prevention|prevent]], delay onset, and/or decrease the severity of PPE. General measures include:<ref name="pmid2061446">{{cite journal| author=Baack BR, Burgdorf WH| title=Chemotherapy-induced acral erythema. | journal=J Am Acad Dermatol | year= 1991 | volume= 24 | issue= 3 | pages= 457-61 | pmid=2061446 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2061446 }} </ref> <ref name="pmid10071309">{{cite journal| author=Susser WS, Whitaker-Worth DL, Grant-Kels JM| title=Mucocutaneous reactions to chemotherapy. | journal=J Am Acad Dermatol | year= 1999 | volume= 40 | issue= 3 | pages= 367-98; quiz 399-400 | pmid=10071309 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10071309 }} </ref> <ref name="pmid15341880">{{cite journal| author=Lassere Y, Hoff P| title=Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). | journal=Eur J Oncol Nurs | year= 2004 | volume= 8 Suppl 1 | issue= | pages= S31-40 | pmid=15341880 | doi=10.1016/j.ejon.2004.06.007 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15341880 }} </ref> <ref name="pmid12660565">{{cite journal| author=Gerbrecht BM| title=Current Canadian experience with capecitabine: partnering with patients to optimize therapy. | journal=Cancer Nurs | year= 2003 | volume= 26 | issue= 2 | pages= 161-7 | pmid=12660565 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12660565 }} </ref> | ||
* Avoiding excessive manual work and walking, to prevent excessive pressure or friction to the skin | * Avoiding excessive manual work and walking, to [[Prevention|prevent]] excessive pressure or [[friction]] to the [[skin]] | ||
* Wound care to prevent infection | *[[Wound]] care to [[Prevention|prevent]] [[infection]] | ||
* Limb elevation to reduce edema | *[[Limb]] elevation to reduce [[edema]] | ||
* Cold compresses | *[[Cold compression therapy|Cold compresses]] | ||
* Avoiding extreme temperatures | * Avoiding extreme [[temperatures]] | ||
* Analgesics | *[[Analgesic|Analgesics]] | ||
* Creams and emollients | * Creams and [[Emollient|emollients]] | ||
==References== | ==References== | ||
Latest revision as of 19:27, 8 August 2019
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia primary prevention On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia primary prevention |
|
Palmar plantar erythrodysesthesia primary prevention in the news |
|
Blogs on Palmar plantar erythrodysesthesia primary prevention |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
|
Risk calculators and risk factors for Palmar plantar erythrodysesthesia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]
Overview
Avoiding excessive manual work and walking, wound care to prevent infection, limb elevation, cold compresses, avoiding extreme temperatures, analgesics, and creams/emollients are suggested to prevent, delay onset, and/or decrease the severity of palmar plantar erythrodysesthesia (PPE).
Primary Prevention
A number of measures have been suggested to prevent, delay onset, and/or decrease the severity of PPE. General measures include:[1] [2] [3] [4]
- Avoiding excessive manual work and walking, to prevent excessive pressure or friction to the skin
- Wound care to prevent infection
- Limb elevation to reduce edema
- Cold compresses
- Avoiding extreme temperatures
- Analgesics
- Creams and emollients
References
- ↑ Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
- ↑ Susser WS, Whitaker-Worth DL, Grant-Kels JM (1999). "Mucocutaneous reactions to chemotherapy". J Am Acad Dermatol. 40 (3): 367–98, quiz 399-400. PMID 10071309.
- ↑ Lassere Y, Hoff P (2004). "Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)". Eur J Oncol Nurs. 8 Suppl 1: S31–40. doi:10.1016/j.ejon.2004.06.007. PMID 15341880.
- ↑ Gerbrecht BM (2003). "Current Canadian experience with capecitabine: partnering with patients to optimize therapy". Cancer Nurs. 26 (2): 161–7. PMID 12660565.